# NOVO-B.CO - Novo Nordisk A/S

> **Analysis Date:** 2026-02-04
> **Analyst:** Claude (Framework v3.0)
> **Status:** RESEARCH
> **Ticker:** NOVO-B.CO (Copenhagen) / NVO (NYSE ADR)

---

## TL;DR

Novo Nordisk, the GLP-1 pioneer behind Ozempic and Wegovy, has collapsed 50%+ from 2024 highs due to: (1) disappointing 2026 guidance (-5% to -13% sales decline), (2) Eli Lilly taking GLP-1 market leadership, and (3) CagriSema trial results below elevated expectations. At ~307 DKK, the stock trades at P/E ~13x (vs historical 25-35x) with ROIC >20%, FCF margin >25%, and dominant positions in a $60B+ TAM growing to $170B by 2033. This is a Quality Compounder (QS 82) temporarily mispriced due to competition fears and guidance reset. Fair Value 450-520 DKK implies 45-70% upside with MoS ~20-30%.

---

## Quality Score: 82/100 - Tier A (Quality Compounder)

### Detailed Breakdown

#### FINANCIAL QUALITY (36/40)

| Metric | Value | Points | Notes |
|--------|-------|--------|-------|
| **ROIC Spread** | ROIC 22% - WACC 6.4% = +15.6pp | **15/15** | Exceptional value creation |
| **FCF Margin** | >25% | **10/10** | Converts >120% net income to FCF |
| **Leverage** | Net Debt/EBITDA <1x (essentially net cash) | **10/10** | Pristine balance sheet |
| **FCF Consistency** | 5/5 years positive | **5/5** | Flawless cash generation |
| **Subtotal** | | **36/40** | Elite financial quality |

#### GROWTH QUALITY (20/25)

| Metric | Value | Points | Notes |
|--------|-------|--------|-------|
| **Revenue CAGR 5yr** | ~18-20% | **10/10** | Exceptional (GLP-1 driven) |
| **EPS CAGR 5yr** | ~15%+ | **10/10** | Strong operating leverage |
| **Gross Margin Trend** | Declining from 85% to 76% (Q3 2025) | **0/5** | Pricing pressure + rebates |
| **Subtotal** | | **20/25** | Growth strong but margin compression |

#### MOAT EVIDENCE (19/25)

| Metric | Value | Points | Notes |
|--------|-------|--------|-------|
| **GM Premium vs Sector** | 76-85% vs Pharma median 67% = +9-18pp | **10/10** | Superior pricing power |
| **Market Position** | #2 in GLP-1 (was #1), ~49% share | **5/8** | Lost leadership to Lilly |
| **ROIC Persistence** | 10/10 years ROIC > WACC | **7/7** | Decade of value creation |
| **Subtotal** | | **19/25** | Strong moat but competitive pressure |

#### CAPITAL ALLOCATION (7/10)

| Metric | Value | Points | Notes |
|--------|-------|--------|-------|
| **Shareholder Returns** | 20+ years dividends, 22% CAGR 5yr | **5/5** | Exceptional track record |
| **Insider Ownership** | ~1.5% insiders, Novo Foundation controls | **2/5** | Foundation alignment > insider buys |
| **Subtotal** | | **7/10** | Good but no recent insider buying |

### QUALITY SCORE TOTAL: 82/100 - TIER A

**Interpretation:** Elite Quality Compounder experiencing temporary competitive headwinds. Tier A status means MoS requirement is 10-15%, but given recent guidance shock and uncertainty, I apply Tier A + Adjustment = 15-20% MoS.

---

## Business Understanding

### What Problem Does Novo Nordisk Solve?

Novo Nordisk addresses two massive global health crises:

1. **Type 2 Diabetes**: 537 million adults globally (1 in 10), projected to reach 783 million by 2045
2. **Obesity**: 1 billion adults globally (13% of population), linked to 200+ comorbidities

GLP-1 receptor agonists (semaglutide) provide:
- Superior glycemic control (HbA1c reduction)
- Significant weight loss (15-22% body weight)
- Cardiovascular risk reduction
- Potential for multiple indication expansion (NASH, Alzheimer's, etc.)

### Revenue Model

| Segment | % Revenue | Key Products | Characteristics |
|---------|-----------|--------------|-----------------|
| **Diabetes Care** | ~60% | Ozempic (semaglutide), Rybelsus (oral) | Chronic, subscription-like |
| **Obesity Care** | ~30% | Wegovy (semaglutide), Saxenda | High-growth, competitive |
| **Rare Disease** | ~10% | Hemophilia, growth disorders | Stable, niche |

**Revenue Type:** Chronic medication = highly recurring. Patients stay on GLP-1s for years/decades.

### Unit Economics

```
Cost to manufacture semaglutide: ~$20-30/month
Wholesale price (US): $900-1,200/month (pre-rebate)
Net price (post-rebate): ~$500-700/month
Gross Margin: ~85% (pre-rebate pressure), declining to 76%

Patient LTV: $50,000-100,000+ (chronic use 5-10+ years)
CAC: Primarily DTC advertising + physician education
LTV/CAC: Estimated >10x (exceptional)
```

**Key Insight:** The unit economics are phenomenal, but competition and rebate pressure are compressing realized prices.

### Why Is It Cheap? (CRITICAL ANALYSIS)

#### The Market Narrative

1. **Eli Lilly dominance**: Zepbound/Mounjaro took 59% of new prescriptions (vs Wegovy 40%)
2. **2026 guidance disaster**: Sales expected to DECLINE 5-13% (first decline in a decade)
3. **CagriSema disappointment**: 22.7% weight loss (vs 25% target) underwhelmed
4. **Patent cliff 2026+**: Semaglutide losing exclusivity in Canada, Brazil, China
5. **Trump price pressure**: Agreement requires lower prices in US
6. **Compounded GLP-1s**: Up to 1.5 million Americans using generic versions

#### My Counter-Thesis

| Market Believes | I Believe | My Evidence |
|-----------------|-----------|-------------|
| Lilly will dominate permanently | Duopoly will persist | GLP-1 TAM is $170B by 2033 - room for both |
| 2026 guidance = new normal | 2026 is trough year | Wegovy pill strong launch (50k scripts/week), CagriSema approval 2026 |
| CagriSema failed | CagriSema is solid | 22.7% weight loss is superior to Wegovy alone (16%), FDA filing accepted |
| Competition destroys moat | Manufacturing scale is moat | Lilly and Novo are only players with global scale for GLP-1 production |
| Price pressure is terminal | Volume will offset price | Obesity penetration is <5% of addressable population |

#### Valuation Sanity Check

| Metric | Current | Historical | Interpretation |
|--------|---------|------------|----------------|
| P/E | ~13x | 25-35x | 50% discount to history |
| EV/EBITDA | ~8x | 15-20x | Deep value for compounder |
| FCF Yield | ~8% | 3-4% | Rarely this cheap |
| Dividend Yield | ~3.2% | 1-2% | 1.5x historical yield |

**The market is pricing Novo like it's in terminal decline. I believe this is a trough, not a trend.**

### Value Trap Checklist

| Factor | Assessment | Notes |
|--------|------------|-------|
| Industry in secular decline | **NO** | GLP-1 TAM growing 17% CAGR to $187B by 2032 |
| Technological disruption | **PARTIAL** | Competition yes, disruption no |
| Management destroying value | **NO** | M&A (Akero, Metsera) strategic |
| Balance sheet deteriorating | **NO** | Net cash position, A+ credit |
| Insider selling massively | **CAUTION** | No insider buying, routine sales |
| Dividend cut probable | **NO** | 49% payout, well covered |
| Market share loss | **YES** | 55% -> 49% GLP-1 share |
| ROIC < WACC | **NO** | ROIC 22% >> WACC 6% |
| FCF negative | **NO** | >$10B annual FCF |
| Goodwill >50% equity | **NO** | Minimal goodwill |

**Value Trap Score: 2/10** - NOT a value trap. Competition is real but not fatal.

### Catalizadores

| Catalyst | Timeline | Probability | Impact |
|----------|----------|-------------|--------|
| Wegovy pill ramp | Q1-Q2 2026 | **HIGH** | +5-10% revenue |
| CagriSema FDA approval | H2 2026 | **MEDIUM-HIGH** | +15-20% to sentiment |
| CagriSema vs Zepbound head-to-head data | Q1 2026 (March) | **MEDIUM** | +/-20% volatility |
| 2026 guidance proves conservative | H2 2026 | **MEDIUM** | Multiple re-rating |
| Obesity indication expansions | 2026-2027 | **MEDIUM** | TAM expansion narrative |
| Acquisition by larger pharma (defensive) | 2026-2027 | **LOW** | +30-50% premium |

### Kill Conditions

1. **CagriSema head-to-head shows inferiority to Zepbound** (data March 2026) - would cement #2 position with inferior product
2. **Market share falls below 40%** - indicates structural competitive disadvantage
3. **Gross margin falls below 70%** - indicates moat erosion
4. **Dividend cut** - would signal management pessimism
5. **ROIC falls below WACC for 2+ years** - value destruction

---

## Projection Framework

### Revenue Projection (NOT using defaults)

#### TAM Analysis

| Market | 2025 | 2030E | 2033E | CAGR |
|--------|------|-------|-------|------|
| GLP-1 Total | $63B | $130B | $170B | 13-17% |
| Diabetes (semaglutide) | $40B | $55B | $65B | 6% |
| Obesity | $20B | $70B | $100B | 22% |

**Source:** Grand View Research, Goldman Sachs estimates

#### Market Share Projection

| Scenario | 2025 Share | 2028 Share | Rationale |
|----------|------------|------------|-----------|
| Bear | 49% | 35% | CagriSema fails, Lilly dominates |
| Base | 49% | 42% | Duopoly stabilizes, share loss slows |
| Bull | 49% | 48% | CagriSema wins, oral Wegovy gains traction |

#### Revenue Growth Derivation

```
TAM Growth (2025-2028): +15% CAGR (weighted diabetes + obesity)
Market Share Change: -2pp/year (base case)
Pricing: -3%/year (net, post-rebate)
= Revenue Growth: 15% - 2% - 3% = ~10% CAGR (normalized post-2026 trough)

2026 Specific:
- Guidance: -5% to -13% (midpoint -9%)
- My expectation: -5% (guidance is conservative)

Post-2026:
- 2027: +8% (recovery, CagriSema launch)
- 2028: +12% (CagriSema + oral ramp)
- 2029-2030: +10% (normalized)
```

### Margin Projection

| Metric | 2025 | 2026E | 2027E | 2028E | Notes |
|--------|------|-------|-------|-------|-------|
| Gross Margin | 82% | 78% | 77% | 76% | Price pressure continues |
| Operating Margin | 43% | 38% | 40% | 42% | Trough in 2026, then leverage |
| FCF Margin | 28% | 22% | 25% | 27% | Capex peaks in 2026 |

### WACC Calculation (NOT using default)

```
Risk-Free Rate (10Y US Treasury): 4.0%
Beta: 0.6 (healthcare defensive, but higher than historical 0.36 due to recent volatility)
Equity Risk Premium: 5.0%
Cost of Equity = 4.0% + 0.6 * 5.0% = 7.0%

Debt/Equity: ~5% (essentially equity-financed)
Cost of Debt (after-tax): ~3.5%

WACC = 95% * 7.0% + 5% * 3.5% = 6.8%

Using 7% WACC for conservatism (slightly above calculated)
```

### Terminal Growth

```
GDP Long-term: 2-3%
Healthcare premium: +0.5%
Terminal Growth: 2.5%

Justification: Diabetes/obesity are chronic conditions with aging population tailwind.
```

---

## Valuation Multi-Method (Tier A: OEY + Reverse DCF)

### Method 1: Owner Earnings Yield (Primary - 60% weight)

```
2025E Financials:
- Revenue: DKK 309B
- Operating Income: DKK 130B (42% margin)
- Net Income: DKK 100B
- FCF: DKK 87B (FCF margin 28%)
- Depreciation: DKK 10B
- Maintenance Capex: ~DKK 11B (D&A * 1.1)

Owner Earnings = FCF - Growth Capex + D&A
= 87B - 15B (excess capex) = DKK 72B

Market Cap (current): DKK 1.35T (at 307 DKK, 4.4B shares)

Owner Earnings Yield = 72B / 1,350B = 5.3%

Expected Growth (normalized): 10%
OEY + Growth = 5.3% + 10% = 15.3%

Rule: OEY + Growth > 12% = BUY
Result: 15.3% > 12% = COMPRAR
```

**Fair Value via OEY:**
```
Target OEY = 3.5% (fair for compounder)
Fair Value Market Cap = 72B / 3.5% = DKK 2.06T
Fair Value per Share = 2.06T / 4.4B = DKK 468

OR

Target OEY + Growth = 12% (minimum return)
Required OEY = 12% - 10% = 2%
Fair Value Market Cap = 72B / 2% = DKK 3.6T
Fair Value per Share = DKK 818 (ceiling)

Conservative Target (4% OEY): DKK 409
Aggressive Target (3% OEY): DKK 545
```

**OEY Method Fair Value: DKK 450 (conservative) to DKK 545 (base)**

### Method 2: Reverse DCF (Secondary - 40% weight)

**Question:** What growth rate is implied in the current price?

```
Current Price: DKK 307
Market Cap: DKK 1.35T
Enterprise Value: ~DKK 1.40T (minimal net debt)

2025 FCF: DKK 87B
WACC: 7%
Terminal Growth: 2.5%

Solving for implied growth:

At 307 DKK, the market implies:
- Years 1-5 growth: -3% to 0%
- Terminal growth: 2.5%

This means the market expects NO growth for 5 years.
```

**My Base Case Growth: +5% CAGR (2026-2030)**

```
If I assume:
- 2026: -5% (guided)
- 2027: +8%
- 2028: +12%
- 2029: +10%
- 2030: +8%
= ~5% CAGR

DCF with these assumptions:
Year 1 FCF: 82.6B (-5%)
Year 2 FCF: 89.2B (+8%)
Year 3 FCF: 99.9B (+12%)
Year 4 FCF: 109.9B (+10%)
Year 5 FCF: 118.7B (+8%)
Terminal Value: 118.7B * 1.025 / (0.07 - 0.025) = 2.70T

PV of Year 1-5 FCF: ~380B
PV of Terminal Value: ~1.93T
Enterprise Value: ~2.31T
Less Net Debt: ~50B
Equity Value: ~2.26T
Per Share: DKK 514
```

**Reverse DCF Method Fair Value: DKK 514**

### Method 3: P/E Normalized (Sanity Check)

```
2025 EPS: DKK 23.33
2026E EPS: DKK 20-22 (guidance implies decline)
Normalized EPS (mid-cycle): DKK 22

Historical P/E: 25-35x
Current P/E: 13x
Sector P/E (Big Pharma): 15-20x
Compounder P/E (reasonable): 20-25x

Fair Value at 20x: 22 * 20 = DKK 440
Fair Value at 25x: 22 * 25 = DKK 550
Fair Value at 18x (conservative): 22 * 18 = DKK 396
```

**P/E Method Range: DKK 400-550**

### Weighted Fair Value

| Method | Fair Value | Weight | Contribution |
|--------|------------|--------|--------------|
| Owner Earnings Yield | DKK 475 (midpoint 450-500) | 60% | DKK 285 |
| Reverse DCF | DKK 514 | 40% | DKK 206 |
| **Weighted Average** | | 100% | **DKK 491** |

**P/E sanity check:** DKK 491 / 22 EPS = 22x P/E - reasonable for quality compounder.

---

## Scenarios

### Bear Case (25% probability)

**Assumptions:**
- CagriSema fails vs Zepbound
- Market share falls to 35%
- Gross margin compresses to 70%
- Revenue declines 5%/year for 3 years
- P/E compression to 15x

```
2028E EPS: DKK 16
P/E: 15x
Fair Value Bear: DKK 240
```

### Base Case (50% probability)

**Assumptions:**
- Duopoly stabilizes at ~42% share
- CagriSema approved and gains traction
- Revenue grows 5% CAGR post-2026
- Operating margin stabilizes at 40%
- P/E normalizes to 20-22x

```
2028E EPS: DKK 25
P/E: 20x
Fair Value Base: DKK 500
```

### Bull Case (25% probability)

**Assumptions:**
- CagriSema shows superiority to Zepbound
- Oral Wegovy captures significant share
- Market share recovers to 48%
- New indications (NASH, Alzheimer's) expand TAM
- P/E re-rates to 25x

```
2028E EPS: DKK 30
P/E: 25x
Fair Value Bull: DKK 750
```

### Expected Value

```
EV = (Bear * 25%) + (Base * 50%) + (Bull * 25%)
EV = (240 * 0.25) + (500 * 0.50) + (750 * 0.25)
EV = 60 + 250 + 187.5
EV = DKK 497.5

Current Price: DKK 307
MoS vs Expected Value: (497.5 - 307) / 497.5 = 38%
MoS vs Base Case: (500 - 307) / 500 = 39%
MoS vs Bear Case: (307 - 240) / 307 = 22% (downside cushion)
```

---

## Margin of Safety Analysis

| Metric | Value | Required (Tier A) | Status |
|--------|-------|-------------------|--------|
| MoS vs Expected Value | 38% | 10-15% | **EXCEEDS** |
| MoS vs Base Case | 39% | 10-15% | **EXCEEDS** |
| MoS vs Bear Case | 22% downside cushion | Positive | **OK** |

**Adjusted MoS Requirement:**
Given recent guidance shock and CagriSema head-to-head uncertainty (March 2026), I apply Tier A + 5% adjustment = 15-20% MoS required.

**Result:** 38% MoS >> 20% required. **SIGNIFICANT MARGIN OF SAFETY.**

---

## Risk Assessment

### Key Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| CagriSema vs Zepbound inferiority | 30% | High | Wait for March data |
| Continued market share loss | 40% | Medium | Priced in at current levels |
| US price pressure accelerates | 50% | Medium | Volume growth offsets |
| Compounded GLP-1 proliferation | 40% | Medium | Quality/safety concerns limit |
| Patent cliff (2026+) | Certain | Medium | Ex-US only, new formulations |
| Regulatory (IRA expansion) | 20% | High | Industry-wide, not Novo-specific |

### Risk-Adjusted Position Sizing

Given QS 82 (Tier A) but elevated near-term uncertainty:
- Base Size: 5%
- Risk Adjustment: -1% (CagriSema data pending)
- Recommended Position: **4% initial**
- Add to 6-7% if CagriSema data is positive

---

## Investment Decision

### 8 Gates Checklist

| Gate | Status | Notes |
|------|--------|-------|
| 1. Quality Score | PASS | QS 82/100, Tier A |
| 2. Business Understanding | PASS | GLP-1 leader, duopoly dynamics clear |
| 3. Projection Fundamentals | PASS | TAM, share, pricing derived |
| 4. Valuation Multi-Method | PASS | OEY + Reverse DCF, P/E sanity check |
| 5. Margin of Safety | PASS | 38% >> 15-20% required |
| 6. Macro Context | PASS | Healthcare defensive, pharma neutral in world view |
| 7. Portfolio Fit | TBD | Check vs current holdings |
| 8. Autocr√≠tica | PASS | See META-REFLECTION below |

### Recommendation

**VERDICT: BUY - Tier A Quality Compounder at distressed valuation**

| Metric | Value |
|--------|-------|
| Entry Price | DKK 307 (current) |
| Fair Value (Weighted) | DKK 491 |
| Target Price (1yr) | DKK 400-450 |
| Target Price (3yr) | DKK 500-600 |
| Upside to FV | +60% |
| MoS | 38% |
| Position Size | 4% initial, scale to 6% on positive catalysts |

### Entry Strategy

**Phased Entry Recommended:**
1. **Initial Position (2%):** At current ~307 DKK
2. **Add (2%):** If CagriSema vs Zepbound data is positive (March 2026)
3. **Add (2%):** On CagriSema FDA approval

**Standing Order:**
- If price drops to DKK 270-280 (Bear case level): ADD aggressively to 6%

### Exit Strategy

| Trigger | Action |
|---------|--------|
| Price = DKK 400 (80% of FV) | Sell 25% |
| Price = DKK 500 (FV) | Sell 50% (cumulative 75%) |
| Price = DKK 600 (Bull FV) | Sell remainder |
| Kill condition triggered | Sell 100% |

---

## Sector View Update

**Action Required:** Update `world/sectors/pharma-healthcare.md`:
- Move NOVO-B.CO from "Evitar" (NVO was listed there due to high valuation) to "Analizadas - En Watchlist"
- Add to "Dependencias Activas" when position established
- Note: At DKK 307 (vs DKK 700-750 when listed as "Evitar"), valuation thesis has completely changed

---

## META-REFLECTION

### Incertidumbres/Dudas

1. **CagriSema vs Zepbound head-to-head data (March 2026)** is THE critical near-term catalyst. The thesis assumes "acceptable" results, but inferiority would be thesis-damaging.

2. **Gross margin trajectory** is unclear - the decline from 85% to 76% is significant. Is this trough or trend? I assumed trough at 76%, but if it continues to 70%, valuation models need revision.

3. **Insider lack of buying** despite 50%+ stock drop is concerning. Either they see structural issues, or they're restricted due to information asymmetry. Cannot determine which.

4. **Oral GLP-1 market share dynamics** are highly uncertain. Goldman projects Lilly at 60% vs Novo at 21%. If correct, oral market is lost.

### Asunciones que podrian ser falsas

1. **TAM grows as projected ($170B by 2033)**: If obesity drugs face safety scares or insurance coverage limits, TAM could be 50% lower.

2. **Duopoly persists**: Pfizer (Metsera), Roche, Amgen, and others are developing GLP-1s. If market fragments, both Lilly and Novo margins suffer.

3. **2026 is trough**: Management said "it will get worse before it gets better." What if 2027 is also bad?

4. **Price decline offsets volume**: I assumed volume growth exceeds price decline. If price decline accelerates faster than volume, revenue stagnates.

### Sugerencias de Mejora del Sistema

1. **Create pharma-specific valuation tool**: DCF for pharma should incorporate patent expiry NPV separately from base business.

2. **Add catalyst-dependent position sizing**: Framework should allow for "hold cash for catalyst" strategy explicitly.

3. **Update sector view status for NOVO**: The sector view lists NVO as "Evitar" at P/E 15.6x - this is now outdated at P/E 13x.

### Preguntas para Orchestrator

1. **Should we wait for CagriSema head-to-head data (March 2026) before initiating position?** The data is <60 days away and could move stock +/-20%.

2. **How does this fit with existing PFE position?** Both are pharma, both are GLP-1 exposed (Pfizer via Metsera acquisition). Is this over-concentration in GLP-1 theme?

3. **Currency consideration:** Stock is in DKK. Should we factor DKK/EUR or use NVO (USD ADR) for execution simplicity?

### Anomalias Detectadas

1. **yfinance rate limited** - Could not pull live data. Used web search data which may be delayed.

2. **Divergent beta estimates**: Sources report beta from 0.36 to 0.95. Used 0.6 as midpoint but this affects WACC significantly.

3. **2026 guidance range is unusually wide** (-5% to -13% = 8pp spread). Management uncertainty is elevated.

---

## Sources

- [Novo Nordisk 2025 Annual Results Press Release](https://www.globenewswire.com/news-release/2026/02/03/3231383/0/en/Novo-Nordisk-s-sales-increased-by-6-in-Danish-kroner-and-by-10-at-constant-exchange-rates-to-DKK-309-1-billion-in-2025.html)
- [Yahoo Finance NOVO-B.CO](https://finance.yahoo.com/quote/NOVO-B.CO/)
- [Euronews: Novo Nordisk stock sinks after 2026 forecast](https://www.euronews.com/business/2026/02/04/novo-nordisk-stock-sinks-by-17-after-bleak-2026-forecast)
- [CNBC: Novo Nordisk stock tumbles after FY earnings](https://www.cnbc.com/2026/02/03/novo-nordisk-2025-earnings-wegovy-ozempic.html)
- [GLP-1 Market Analysis - Motley Fool](https://www.fool.com/investing/2026/01/13/eli-lilly-vs-novo-nordisk-which-to-dominate-2026/)
- [Novo Nordisk ROIC - GuruFocus](https://www.gurufocus.com/term/roic/NVO)
- [MacroTrends: Novo Nordisk Margins](https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/gross-margin)
- [Stock Analysis: NVO Financials](https://stockanalysis.com/stocks/nvo/financials/ratios/)
- [CagriSema Phase 3 Results - Clinical Trials Arena](https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-outperforms-ozempic-in-phase-iii-trial/)
- [Novo Nordisk Dividend History](https://www.novonordisk.com/investors/stock-information/dividend.html)
- [Alpha Spread: NVO WACC](https://www.alphaspread.com/security/nyse/nvo/discount-rate)
